More info
Active ingredients
Diphenhydramine + Naphazoline + Zinc Sulfate
Release form
Drops
Composition
Diphenhydramine hydrochloride 1 mg, naphazoline hydrochloride 1 mg, zinc sulfate 1 mg Auxiliary substances: sodium citrate 14 mg, citric acid 0.6 mg, benzalkonium chloride 0.2 mg, dye blue methylene 0.03 mg, sodium chloride 3.2 mg, hypromellose 4000 0.25 mg, sodium hydroxide 0.3 mg, distilled water to 1 ml.
Pharmacological effect
Okumetil is a combination drug containing zinc sulfate, diphenhydramine and naphazoline. Zinc sulfate, when applied topically, has a binder, drying, anti-inflammatory and antiseptic effect. Naphazoline is a sympathomimetic. It has a fast, pronounced and prolonged vasoconstrictor effect. When applied topically, it reduces swelling and hyperemia of the mucous membranes. Diphenhydramine is a blocker of H1-histamine receptors. When applied topically, it reduces the permeability of capillaries and prevents swelling of tissues. Thus, Okumetil has an antiseptic, antiallergic and anti-inflammatory effect.
Pharmacokinetics
When applied topically, it undergoes systemic absorption. Information on the degree of penetration into various tissues of the eye after topical application.
Indications
- chronic nonspecific conjunctivitis and blepharoconjunctivitis; - allergic conjunctivitis and blepharoconjunctivitis; - angular conjunctivitis; - reduction of eye tissue irritation symptoms (redness, itching, foreign body sensation).
Contraindications
- hypersensitivity to the components of the drug; - angle-closure glaucoma; - dry eye syndrome; - pregnancy; - lactation; - prostate gland hyperplasia; stenosing gastric and duodenal ulcer; bladder neck stenosis; - bronchial asthma; - epilepsy; diseases (IHD, arterial hypertension); - pheochromocytoma; - hyperfunction of the thyroid gland; - diabetes mellitus; - pronounced atherosclerosis; - children's age up to 2 years.
Precautionary measures
Do not exceed the recommended dose. Use with caution in patients taking MAO inhibitors or other drugs that increase blood pressure
Use during pregnancy and lactation
The drug is contraindicated for use during pregnancy and lactation.
Dosage and administration
Locally. If there are no other doctor’s prescriptions, bury 1 drop in the conjunctival sac of the affected eye (s) 2-3 times a day. If there is no decrease in symptoms during the 72 hours of use, you should stop using the drug and consult a doctor.
Side effects
After instillation, a feeling of slight burning, blurring of vision, the development of allergic reactions may occur. When aphakia may develop maculopathy and the emergence of a central scotoma. In this case, the abolition of the drug leads to the reverse development of symptoms. After the local use of naphazoline, which is part of Okumetil, reactive hyperemia and swelling of the mucous membrane of the eyes, dilated pupils, increased IOP (intraocular pressure) may occur. With prolonged use, the phenomenon of tissue irritation occurs most often. As with topical administration, naphazoline has a general resorptive effect, it is possible to develop tachycardia, increase blood pressure, nausea, and headache. With local application of diphenhydramine, side effects of both local and systemic nature may occur: paresis of accommodation, photosensitivity, dryness and numbness of the mucous membranes of the eyes, drowsiness, weakness, decreased psychomotor reactions and impaired coordination of movement dizziness. With long-term use of zinc salts, dry eye mucosa may occur.
Overdose
Data overdose of the drug is not available.
Interaction with other drugs
Since it is possible to reduce the effects of diphenhydramine and medications that stimulate the central nervous system, it is not recommended to use Okumetil in patients using these drugs. Okumel should not use simultaneous MAO inhibitors for 10 days after stopping their use. As a result of the combined use of beta-adrenergic blockers, MAO inhibitors with adrenomimetics, the action of the latter is enhanced. Naphazoline slows down the absorption of local anesthetic agents, therefore combined use of the drug Okumetil with local anesthetics used in ophthalmology is not recommended. Zinc sulfate is not pharmaceutically compatible with silver salts, lead, quinine, ichthyol, citral, protargol, alkaline-reactive substances.
special instructions
To avoid contamination of the solution, keep the vial tightly closed and avoid contact of the pipette tip with any surface. Impact on ability to drive vehicles and control mechanisms Within 10-15 minutes after installation, visual acuity may decrease, and therefore care must be taken when driving car and when working with mechanisms.